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Introduction
The possible benefit of self-monitoring of blood glucose (SMBG) in noninsulin-treated persons with type 2 diabetes has been the topic of several studies summarized in two position statements.
1,2 Three recent meta-analyses of randomized trials came to the conclusion that SMBG as part of a multicomponent treatment strategy in noninsulin-treated type 2 diabetes led to significantly stronger reduction of HbA1c levels. [3] [4] [5] Because none of the prospective studies extended beyond 1 year, the long-term outcome in relation to SMBG is not known.
Self-monitoring of blood glucose represents a diagnostic measure that by itself has no impact on disease course. Relevant for outcome are consequences taken because of SMBG results. These consequences include patient's attitude toward the disease, adaptation of lifestyle, or modification of antidiabetic therapy and appropriate education by the treating physician.
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The advantage of an observational trial is that it incorporates all of these SMBG-associated changes of attitude and treatment, as occurring in the unperturbed daily practice. In addition, long-term outcomes can be analyzed. The disadvantage is the lack of randomization, i.e., patient cohorts with or without SMBG differ somewhat in baseline characteristics, which may affect outcome. Therefore, nonrandomized studies are not suitable to prove a cause and effect relationship. Nevertheless, epidemiological studies can provide valuable information about the use of SMBG and associated outcomes. Relevant questions are whether patients performing SMBG are different by clinical or demographic characteristics and whether the use of SMBG is associated with different types of antidiabetic therapy prescribed or with extent and quality of comedication.
The German multicenter, retrospective cohort study (ROSSO) analyzed more than 3000 patients from diagnosis of type 2 diabetes for a mean of 6.5 years. 11 The cohort comprised patients treated with diet only, with oral antidiabetic drugs (OAD), or with insulin. When all patients were analyzed together, the use of SMBG was associated with a lower risk of diabetes-related nonfatal events or death. 11 The aim of this analysis was to evaluate the course of disease in OAD-treated patients of the ROSSO cohort and to identify SMBG-associated differences in patient characteristics, treatment, and outcome.
Materials and Methods

Subjects and Study Design
The design of ROSSO has been reported previously, as well as the participating centers of the ROSSO Study Group.
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In brief, a retrospective, comparative, epidemiological cohort study was performed in collaboration with 192 nonselected primary care practices throughout Germany. Of these practices, 143 (74.5%) were managed by a general practitioner and 49 (25.5%) by an internist. Based on patient files, data were collected from all patients diagnosed with type 2 diabetes between January 1, 1995 and December 31, 1999. Data were validated by monitors visiting the practices. Persons with a diabetes diagnosis prior to the age of 45 years or with a documented followup of less than 1 year were excluded.
Patients were followed from the time of diagnosis of diabetes until the end of 2003, or until death or loss to follow-up for other reasons (nine cases). The study protocol was submitted to the ethics committee of the General Medical Council of North-Rhine, Germany.
In total, 3268 patients were available for analyses. Predefined study end points were myocardial infarction, stroke, foot amputation, blindness (one or both eyes), end-stage renal failure requiring hemodialysis, and allcause mortality. The composite end point included all of these events. End points were taken as documented in patient files. Analysis of nonfatal end points was based on the first event occurring in a patient during the observation period. The treating physician defined a patient as performing SMBG in any year based on the prescription of test strips and/or blood glucose data documented by the patient. Clinical chemistry data were from local laboratory analyses. Because HbA1c assays used by different practices were not standardized, all values were adjusted to 6.1% as the upper limit of the normal range of each laboratory.
Statistical Analyses
Differences in numeric baseline and follow-up data between patients with and without SMBG were assessed using two-sided t tests. A p value below 0.05 was considered statistically significant. Differences in incidence proportions of end points were analyzed with Fisher's exact test. Odds ratios for end points were calculated and adjusted to baseline variables with logistic regression. The main target variable was time from the date of diabetes diagnosis until a nonfatal or fatal end point (survival time). Survival analysis was performed based on KaplanMeier estimates. Differences in survival distribution were tested for statistical significance using the log-rank test. Estimates of hazard ratios (HR) and associated 95% confidence intervals (CI) were determined and adjusted for baseline variables by means of Cox regression based on the proportional hazard rate model. SMBG was the primary covariable, and various parameters with potential influence on the end points were further covariables. Statistical analyses were undertaken with SPSS+ for Windows, versions 11.5, 12.0, and 13.0.
Results
The ROSSO cohort comprised 3268 persons followed from diagnosis of type 2 diabetes. Of these, 1912 subjects received oral antidiabetic therapy (sulfonylureas, metformin, α-glucosidase inhibitor, glinides, glitazones) for at least 1 year but no insulin until the end of observation or until a first nonfatal end point. During this period, the use of SMBG for at least 1 year was documented for 38.8% of persons (n = 742), subsequently named the SMBG cohort. At diabetes diagnosis, biochemical and clinical baseline characteristics of the SMBG cohort were not significantly different from the no SMBG cohort except for higher diastolic (p = 0.02) but not systolic blood pressure (p = 0.32) ( Table 1 ).
Baseline differences between the two cohorts were noted with regard to some demographic factors, persons in the SMBG cohort were younger by a mean of 3 years, more often males, more often treated by an internist, lived more often not in a large city, and visited more often a center located in small town/rural areas ( Table 1) . Because only 74 of the 1912 patients were privately insured, their uneven distribution between the two cohorts did not affect any of the analyses described. There was no interaction between smoking status and use of SMBG ( Table 1) .
Information on the Initiation of SMBG
There was a continuous increase of the percentage of patients using SMBG from the year of diagnosis (10.0%) until year 7 (30.2%). The mean time from beginning SMBG to an end point was 2.8 years. Of patients in the SMBG cohort (set as 100%), 13% started with SMBG before and an additional 36% concomitant with OAD treatment and another 51% of patients took up SMBG only after therapy began.
Patients who initiated oral therapy and SMBG in the same year exhibited considerable deterioration of metabolic control before and substantial improvement after the start of OAD therapy and SMBG ( Figures 1A and 1B) . Patients who received OAD already for at least 1 year before the start of SMBG also showed some deterioration of metabolic control prior to and improvement after beginning SMBG (Figures 1C and 1D) . The means of HbA1c of years 5-7 were 7.1, 7.1, and 7.0% for the no SMBG cohort (baseline 7.5%) compared to 7.1, 7.1, and 7.0% for the SMBG cohort (baseline 7.7%). Taken together, the SMBG cohort had slightly poorer metabolic control at baseline and reached the level of the no SMBG cohort later on. a Comprises patients with SMBG (documented for at least 1 year) during the observation period or prior to but not necessarily until a nonfatal end point. b P value for difference between the two subgroups (male sex distribution: Fisher's exact test; other variables: two-sided t test). c HbA1c adjusted to 6.1% as upper limit of normal range using the following formula: (HbA1c/upper limit of normal range) × 6.1.
Antidiabetic Therapy in SMBG versus No SMBG Cohort
About two-thirds of patients received sulfonylurea in both cohorts, but metformin was prescribed more often to patients of the SMBG cohort (74.7% as compared to 65% in the no SMBG cohort, p < 0.001, Table 2 ). α-Glucosidase inhibitors were also prescribed more often to patients of the SMBG cohort (24.5% versus 19.7%, p = 0.02). Because less than 3% of patients received glinides or glitazones, a separate analysis was not conducted. OAD therapy of any type began about the same time in both cohorts (mean of 1.35 years from diagnosis in the SMBG cohort versus 1.49 years in the no SMBG cohort, p = 0.12). The mean time periods until introduction of sulfonylurea, metformin, α-glucosidase inhibitor, or any combination were comparable in the two cohorts ( Table 2) . However, there was a longer duration of treatment with sulfonylurea in the SMBG cohort. Also, the duration with treatment of combinations of oral agents was longer in the SMBG cohort. The combination seen most often was sulfonylurea + metformin (28.7% of patients of the SMBG group versus 24.8% of patients in the no SMBG group, p = 0.06). Finally, the type of pharmacological agents used for therapy was changed more often in the SMBG cohort, i.e., in 66.3% of patients compared to 48.3% of patients in the no SMBG cohort, p < 0.001 ( Table 2) .
Comedication in SMBG versus No SMBG Cohort
Fewer patients in the SMBG cohort were treated with antihypertensive drugs as compared to the no SMBG Table 2 ). No differences were observed with regard to prescriptions for lipid-lowering drugs or thrombocyte aggregation inhibitors ( Table 2 ). The mean duration of treatment was comparable for antihypertensive or lipid-lowering therapy, whereas treatment with thrombocyte aggregation inhibitors was shorter in the SMBG cohort.
Follow-Up of Biochemical and Clinical Parameters
The two cohorts exhibited little differences with regard to the course of BMI, systolic and diastolic blood pressure, total and low-density lipoprotein (LDL) cholesterol, or triglycerides from diagnosis of diabetes (Figure 2) . The possible impact of SMBG can be best analyzed from year 5 on, when >75% of patients in the SMBG cohort performed self-control. In comparison to baseline levels there was a trend toward better levels in the SMBG cohort for total cholesterol and diastolic blood pressure but not for other parameters.
Clinical Outcome in SMBG versus No SMBG Cohort
During the observation period, 223 patients (11.7%) experienced an end point. Of these patients, 155 had not performed SMBG prior to the event ( Table 3) . Odds ratios were calculated after multivariate adjustments for baseline parameters and showed a 28.3% reduction for the composite end point (p = 0.038). As shown in Table 3 , the lower number of events in the SMBG group was primarily a consequence of a lower number of macrovascular end points and decreased mortality. At baseline, the SMBG cohort did not differ significantly from the no SMBG cohort for the prior occurrence of macrovascular events (myocardial infarction 3.8% vs 3.9%, stroke 2.4% vs 2.8%). (Figure 3 ) demonstrated superior survival regarding the composite end point for patients receiving OAD with SMBG over the entire observation period (p = 0.002), adjusted HR 0.69, 95% confidence interval 0.49-0.87, and p = 0.001.
Kaplan-Meier analysis
Discussion
Within the first 8 years after diagnosis of type 2 diabetes, more than one-third of patients began self-monitoring of blood glucose before or during treatment with oral antidiabetic drugs. This figure was unexpected for Germany, as costs of SMBG are usually not reimbursed by public health insurances in the context of OAD therapy, except for possibly a low number of strips.
Is there is special "phenotype" of patients using SMBG in routine primary care? The major differences observed were that future SMBG users were younger by a mean of 3 years at diabetes diagnosis and were more often male than those not using SMBG during the observation period. There were only minor differences in disease characteristics at diagnosis. Although SMBG users were treated more often by an internist, a major influence of qualification of the treating physician was not recognizable, i.e., more than 70 % of patients were in the care of a practitioner in both cohorts.
The motivation to initiate SMBG probably came from a continuous worsening of glycemic control, as documented in the patient files. After the initiation of SMBG, both FBG and HbA1c declined to stable lower levels. The concomitant start of OAD therapy contributed to the improvement in glycemic control. Patients who started with SMBG while on OAD therapy also exhibited deterioration of metabolic control prior to the start of SMBG and improvement thereafter. This suggests a positive impact of SMBG on metabolic control in these patients but does not prove it. It would have been of interest to relate the changes in glycemic control to the frequency of self-monitoring, but such information was documented only rarely. It has been reported in another observational study that more frequent self-monitoring was associated with better levels of glycemic control.
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Another type of information not available from patient files was the occurrence of hypoglycemic episodes so that the relationship to initiation or use of SMBG could not be analyzed.
We searched for differences in pharmacological treatment in relation to SMBG status. Antidiabetic therapy was started at about the same time in the two cohorts when comparing the use of sulfonylurea, metformin, or α-glucosidase inhibitor. A higher percentage of patients in the SMBG cohort received metformin or α-glucosidase inhibitor. Most notably, types of OAD were changed or added significantly more often in the SMBG cohort. These differences in OAD therapy fit with the assumption that SMBG allows for more adaptation of antidiabetic therapy, although this may not be always the case. 13 Treat ment wit h dr ugs modulat i ng t he risk s of macrovascular events, i.e., antihypertensive or lipidlowering drugs and thrombocyte aggregation inhibitors, did not differ in favor of the SMBG cohort when the percentage of patients treated or the mean duration of treatment was compared. Although there is a higher awareness of the disease and its complications in patients using SMBG 14 and a more intense interaction with treating doctors when showing diabetes diaries can be expected, this did not result in recognizable differences of comedication. . Eight patients without a fatal end point (five non-SMBG, three SMBG) had more than one nonfatal end point during follow-up. In the non-SMBG cohort, five patients had myocardial infarction and stroke, whereas in the SMBG cohort, two patients had myocardial infarction and stroke and one patient had stroke and dialysis. Of the 1912 OAD-treated persons analyzed, 223 (11.7%) experienced an end point. Of the latter, more than 80% were macrovascular end points, myocardial infarction, or stroke in both the SMBG and the no SMBG cohort. In the SMBG cohort the HR for an end point was 0.69 (compared to 1.0 for the no SMBG cohort) after adjustment for biochemical, clinical, and demographic differences between the two cohorts at diagnosis of type 2 diabetes, with logistic regression.
The modest differences in antidiabetic therapy may have contributed to the better prognosis in the SMBG cohort.
More frequent adjustments of antidiabetic therapy may have contributed to improvement in metabolic control so that the initially higher levels of HbA1c and FBG levels in the SMBG cohort reached that of the no SMBG cohort. Metabolic control was assessed by FBG and HbA1c only and did not include postprandial glucose levels. Only the latter have been reported to be strong risk factors of macrovascular events in type 2 diabetes. [15] [16] [17] [18] [19] [20] [21] [22] Postprandial glucose is only poorly reflected by FBG or HbA1c.
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An additional factor to be considered is lifestyle. It has been reported previously that dietary and exercise habits have an impact on risk factors of cardiovascular events, such as serum levels of C-reactive protein, adiponectin, or postprandial glucose. [26] [27] [28] [29] [30] A somewhat "healthier" lifestyle of patients performing SMBG is conceivable. 31, 32 We therefore assume that SMBG is associated with different dietary and exercise patterns, leading to a decrease of postprandial glycemia and concomitant oxidative stress in the vasculature. An alternative explanation that cannot be excluded is that persons who take up SMBG present with a different type of disease for genetic or other reasons.
Future randomized prospective trials should include documentation of patients' lifestyle and of postprandial blood glucose levels in order to assess the possible role of these parameters in translating SMBG into clinical benefit.
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